❭ Research by medical division ❭ Cancer Medicine ❭ Institute for Cancer Research ❭ Dept. of Tumor Biology ❭ Translational Cancer Therapy [Flatmark] ❭ Major collaborators

Major collaborators

Academic collaborations

PERIMMUNE

The Section of Cellular Therapy

Pathology Research Radiumhospitalet 

EuroPMP

 

Commercial collaborations

Nadeno

Node

Bayer

 

 

 

 

 
Scroll to top

Home Dept. of Tumor Biology Translational Cancer Therapy [Flatmark]

  • Group members
  • From bench to bedside
  • Interventional clinical trials
  • Target discovery in peritoneal surface malignancies
  • Locally advanced and recurrent rectal cancer
  • Experimental treatment
  • Publications
  • News
  • Major collaborators

Recent publications

Truntzer C, Thibaudin M, Bousquet PA, Peroz M, Derangère V, Ilie A, Rageot D, Flatmark K, Ree AH, Meltzer S, Ghiringhelli F (2026)
Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies
Oncoimmunology, 15 (1), 2671491
DOI 10.1080/2162402X.2026.2671491, PubMed 42322272

Ree AH, Meltzer S, Flatmark K, Dueland S (2026)
Low-intensity induction chemotherapy before chemoradiotherapy for rectal cancer: 10-year overall survival in the LARC-RRP trial
Br J Radiol (in press)
DOI 10.1093/bjr/tqag133, PubMed 42233285

Meltzer S, Landmark SS, Šaltytė Benth J, Negård A, Hamre HM, Kersten C, Hofsli E, Guren MG, Sorbye H, Flatmark K, Ree AH (2026)
Carcinoembryonic Antigen Flare Under Oxaliplatin-Based Chemotherapy Predicts Benefit from Nivolumab in Metastatic Microsatellite-Stable Colorectal Cancer - A Post Hoc Analysis of METIMMOX Trial Data
Immunotargets Ther, 15, 594176
DOI 10.2147/ITT.S594176, PubMed 42158080



More publications

Oslo University Hospital is a part of Southern and Eastern Norway Regional Health Authority.

Webmaster for research pages: Trond Olav Berg

Cookie policy

Accessibility statement (in Norwegian)